🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being viewed as a "huge turning point" in the fight against increasingly resistant strains of the pathogen, according to researchers.

A Worldwide Health Concern

Cases of gonorrhoea are increasing around the world, with data suggesting more than 82 million infections annually. Notably increased rates are reported in Africa and countries within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. Within England, cases have hit a historical peak, while rates across Europe in 2023 were significantly elevated compared to figures for 2014.

“The authorization of fresh medications for gonorrhoea is an important and timely advancement in the reality of increasing worldwide cases, the spread of superbugs and the very limited treatment choices presently on offer.”

Health officials are increasingly worried about the surge in treatment-resistant strains. The global health body has listed it as a "priority pathogen". Ongoing monitoring found that the effectiveness of primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Therapies Gain Authorization

Zoliflodacin, also known as a brand name, was authorized by the American regulatory agency in recent days for treating gonorrhoea. This STI can lead to significant complications, including infertility. Scientists anticipate that focused deployment of this new drug will help delay the emergence of superbugs.

Gepotidacin, developed by the pharmaceutical company GSK, also received approval in concurrent days. This drug, which is also used to treat UTIs, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin stemmed from a innovative non-profit model for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to see it through.

“This authorization signifies a significant shift in the management of superbug gonorrhoea, which until now has been outpacing medical innovation.”

Testing Data and Global Access

As per data released by a major medical journal, zoliflodacin successfully treated over nine in ten of uncomplicated infections. This places it at an similar efficacy with the typical regimen, which involves a dual-drug approach. The research included over 900 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, the non-profit has the ability to register and commercialise the drug in a wide range of regions with limited resources.

Medical professionals directly involved have expressed positive views. Access to a single-dose, oral treatment like this is hailed as a "critical tool" for managing the epidemic. This is considered vital to lessen the impact of the infection for people and to halt the transmission of highly drug-resistant gonorrhoea worldwide.